BioCentury | Jul 19, 2019
Financial News

July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

...company Forendo's syndicate Sunstone Life Science Ventures said it invested €5 million ($5.6 million) in Forendo Pharma Ltd....
...million ($168.9 million). Paul Bonanos, Associate Editor Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Atara Biotherapeutics Inc. Forendo Pharma Ltd. Sunstone...
BioCentury | Nov 9, 2015
Clinical News

Fispemifene: Completed Phase IIb enrollment

...product from Forendo (see BioCentury, Oct. 27, 2014). Apricus Biosciences Inc. (NASDAQ:APRI), San Diego, Calif. Forendo Pharma...
BioCentury | Oct 27, 2014
Financial News

Forendo Pharma completes venture financing

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Date completed: 2014-10-22 Type: Venture financing Raised: EUR3 million ($3.8 million) Investors: Novartis Venture Funds; MS Ventures; Karolinska Development AB ; Novo Seeds; Finnvera Venture Capital Note:...
BioCentury | Oct 27, 2014
Company News

Forendo Pharma, Apricus Biosciences deal

...selective estrogen receptor modulator (SERM) from QuatRx Pharmaceuticals Co. (Ann Arbor, Mich.) in June 2013. Forendo Pharma...
BioCentury | Oct 27, 2014
Company News

Forendo Pharma board of directors update

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Appointed: Hakan Goker, an investment director at MS Ventures; and Anja Konig, managing director at Novartis Venture Fund WIR Staff Genitourinary...
BioCentury | Oct 23, 2014
Financial News

Forendo closes EUR 12M series A

Forendo Pharma Oy (Turku, Finland) closed a EUR 12 million ($15.3 million) series A round led by new investors Novartis Venture Fund and MS Ventures. Existing investors including Karolinska Development AB ; Novo Seeds; and...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

...can focus on the HSD17B1 program. Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Forendo Pharma...
...QuatRx Pharmaceuticals Co. , Ann Arbor, Mich. Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Sidebars Forendo Pharma...
BioCentury | Jul 1, 2013
Financial News

Forendo Pharma completes venture financing

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Date completed: 6/25/13 Type: Venture financing Raised: €3.5 million ($4.6 million) Investors: Karolinska Development AB ; Novo Seeds; Finnvera Venture Capital Note: The company raised €3.5 million...
Items per page:
1 - 8 of 8
BioCentury | Jul 19, 2019
Financial News

July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

...company Forendo's syndicate Sunstone Life Science Ventures said it invested €5 million ($5.6 million) in Forendo Pharma Ltd....
...million ($168.9 million). Paul Bonanos, Associate Editor Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Atara Biotherapeutics Inc. Forendo Pharma Ltd. Sunstone...
BioCentury | Nov 9, 2015
Clinical News

Fispemifene: Completed Phase IIb enrollment

...product from Forendo (see BioCentury, Oct. 27, 2014). Apricus Biosciences Inc. (NASDAQ:APRI), San Diego, Calif. Forendo Pharma...
BioCentury | Oct 27, 2014
Financial News

Forendo Pharma completes venture financing

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Date completed: 2014-10-22 Type: Venture financing Raised: EUR3 million ($3.8 million) Investors: Novartis Venture Funds; MS Ventures; Karolinska Development AB ; Novo Seeds; Finnvera Venture Capital Note:...
BioCentury | Oct 27, 2014
Company News

Forendo Pharma, Apricus Biosciences deal

...selective estrogen receptor modulator (SERM) from QuatRx Pharmaceuticals Co. (Ann Arbor, Mich.) in June 2013. Forendo Pharma...
BioCentury | Oct 27, 2014
Company News

Forendo Pharma board of directors update

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Appointed: Hakan Goker, an investment director at MS Ventures; and Anja Konig, managing director at Novartis Venture Fund WIR Staff Genitourinary...
BioCentury | Oct 23, 2014
Financial News

Forendo closes EUR 12M series A

Forendo Pharma Oy (Turku, Finland) closed a EUR 12 million ($15.3 million) series A round led by new investors Novartis Venture Fund and MS Ventures. Existing investors including Karolinska Development AB ; Novo Seeds; and...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

...can focus on the HSD17B1 program. Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Forendo Pharma...
...QuatRx Pharmaceuticals Co. , Ann Arbor, Mich. Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Sidebars Forendo Pharma...
BioCentury | Jul 1, 2013
Financial News

Forendo Pharma completes venture financing

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Date completed: 6/25/13 Type: Venture financing Raised: €3.5 million ($4.6 million) Investors: Karolinska Development AB ; Novo Seeds; Finnvera Venture Capital Note: The company raised €3.5 million...
Items per page:
1 - 8 of 8